Drugs Made In America Acquisition Corp. Rights

FRC's fair value estimate for Drugs Made In America Acquisition Corp. Rights, and the rating behind it. DMAAR last traded at $0.13, 55.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition Corp. Rights. Starting points for Drugs Made In America Acquisition Corp. Rights: P/E 55.4, EPS $0.30, beta 3.90 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Drugs Made In America Acquisition Corp. Rights. Drugs Made In America Acquisition Corp. Rights does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Drugs Made In America Acquisition Corp. Rights. Trailing twelve-month EPS for Drugs Made In America Acquisition Corp. Rights stands at $0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition Corp. Rights. Drugs Made In America Acquisition Corp. Rights has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Drugs Made In America Acquisition Corp. Rights valued side by side against its closest peers. Drugs Made In America Acquisition Corp. Rights is measured against Shell Companies peers within the Financial Services sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Drugs Made In America Acquisition Corp. Rights, and how their positions are changing. At a $287.8M market value, institutional positions materially move Drugs Made In America Acquisition Corp. Rights's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Drugs Made In America Acquisition Corp. Rights executives and directors. Shares of Drugs Made In America Acquisition Corp. Rights have traded between $0.15 and $0.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Drugs Made In America Acquisition Corp. Rights. Drugs Made In America Acquisition Corp. Rights is a $287.8M Financial Services company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Drugs Made In America Acquisition Corp. Rights. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Drugs Made In America Acquisition Corp. Rights. Coverage tracks Drugs Made In America Acquisition Corp. Rights within Shell Companies (Financial Services). Press releases and market coverage, newest first.